Publications by authors named "M H Kalnoski"
Genomic data provides useful information for public health practice, particularly when combined with epidemiologic data. However, sampling bias is a concern because inferences from nonrandom data can be misleading. In March 2021, the Washington State Department of Health, USA, partnered with submitting and sequencing laboratories to establish sentinel surveillance for SARS-CoV-2 genomic data.
View Article and Find Full Text PDFBackground: In patients with unexplained cytopenias, abnormal karyotyping studies can be found with inconclusive light microscopic findings. Multidimensional flow cytometry (FCM) can identify myelomonocytic cells with aberrant phenotypes often not seen by standard morphology.
Methods: In 431 patients presenting with unexplained cytopenia(s) FCM results were compared to abnormal karyotyping and FISH results recognized as associated with myelodysplastic syndrome (MDS) in the 2008 WHO classification, to assess the degree of and types of phenotypic abnormalities observed using a previously reported flow cytometric scoring system (FCSS).
Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses.
Cytometry B Clin Cytom
January 2009
Article Synopsis
- Flow cytometric enumeration of blasts in bone marrow aspirates is less effective when blood contaminates the sample, with sequential aspirates showing declining blast proportions.
- A study comparing CD16 intensity in neutrophils from bone marrow biopsies and aspirates revealed mixed results, with most cell populations being similar, except in a patient with myelodysplasia.
- To counteract blood dilution effects, three strategies are proposed: using biopsy specimens for blast counts, evaluating aspirates based on mature neutrophil proportions, and using a formula to adjust aspirate results for accurate blast counting.
Background: In this study we demonstrate the technical application of flow cytometry and cell sorting combined with gene-rearrangement clonality profiling to detect and confirm minimal disease in 2 leukemia and 2 lymphoma cases.
Methods: Specimens with low percentages (0.05%-5%) of abnormal lymphoid populations were identified by flow cytometry.
Introduction: The purpose of this study was to estimate, in patients undergoing cardiopulmonary bypass (CPB), the in vivo rates of tissue plasminogen activator (tPA) and plasminogen activator inhibitor 1 (PAI-1) secretion, plasmin generation, fibrin degradation, and plasmin inhibition by aprotinin versus antiplasmin.
Materials And Methods: Estimates of in vivo rates were based on measured levels of tPA, PAI-1, antiplasmin, plasmin-antiplasmin complex (PAP), total aprotinin, plasmin-aprotinin complex and D-dimer, combined with a computer model of each patient's vascular system that continuously accounted for secretion, clearance, hemodilution, blood loss and transfusion. Plasmin regulation was studied in nine control patients undergoing CPB without aprotinin versus six patients treated with aprotinin.